Abstract 546P
Background
More than 70% of patients with T1 colorectal cancer (CRC) undergo a radical surgery involving lymph node dissection, despite the presence of lymph node metastasis (LNM) being observed in only ∼10% of cases. To reduce unnecessary radical surgery, we developed a multimodal artificial intelligence (AI) system to identify T1 CRC at risk for LNM.
Methods
We analyzed 402 CRC patients from two independent multicenter cohorts, including a training (n = 219) and a validation cohort (n = 183). Proteomics dataset from tumor tissue were identified and quantified using LC-MS/MS analysis. Multiple pathomics features were extracted from whole H&E slides with patch-level convolutional neural network training in weakly supervised manner. Clinicopathological characteristics included age, tumor size, location, lymphatic and vascular invasion, perineural invasion, histologic grade, and CEA. A machine-learning artificial neural network using proteomics, pathomics and clinicopathological features was developed.
Results
LNM were detected in 78 out of 219 patients (35.6%) within the training cohort and in 29 out of 183 patients (15.8%) within the validation cohort. A panel of six protein biomarkers (OSBPL5, ATAD2, BAIAP2, MANBA, ITPR2, ARHGAP5) screened by proteomics was quantified by immunohistochemistry and subsequently integrated into the AI system. In the validation cohort, the multimodal AI system achieved robust classification of LNM status, yielding an AUC of 0.978. In comparison, the guideline-based model exhibited an AUC of 0.717 for identifying LNM (P < 0.001).
Conclusions
The AI system integrating deep learning-proteomics, pathomics and clinicopathological features robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. The multimodal AI system would improve clinical practice by alleviating the burden of unnecessary overtreatment for T1 CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jianmin Xu.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15